Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781Phase 4Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2022
- Primary completion
- Jul 2037
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 8
01
Overview
A Phase 4 trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Mar 2022; status: recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05201781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201781.